Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAM: Regorafenib Eye Drops in wAMD
NCT02222207Phase 2Terminated
- Sponsor
- Bayer
- Start
- Oct 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 2 trial of regorafenib eye drops in neovascular age-related macular degeneration (NVAMD), sponsored by Bayer. Started Oct 2014; status: terminated.
02
Drugs
regorafenib eye drops
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02222207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02222207.